BNTX – BioNTech SE
Float Short %
2.54
Margin Of Safety %
Put/Call OI Ratio
0.86
EPS Next Q Diff
0.85
EPS Last/This Y
-0.88
EPS This/Next Y
0.35
Price
96.73
Target Price
141.23
Analyst Recom
1.61
Performance Q
-7.8
Relative Volume
6.7
Beta
1.47
Ticker: BNTX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | BNTX | 113.52 | 0.80 | 0.63 | 51262 |
| 2025-08-18 | BNTX | 112.58 | 0.84 | 0.33 | 47178 |
| 2025-08-19 | BNTX | 111.46 | 0.84 | 0.74 | 47468 |
| 2025-08-20 | BNTX | 111.28 | 0.84 | 0.09 | 48110 |
| 2025-08-21 | BNTX | 110.21 | 0.84 | 0.04 | 48273 |
| 2025-08-22 | BNTX | 110.9 | 0.83 | 0.14 | 48656 |
| 2025-08-25 | BNTX | 105.07 | 0.83 | 0.37 | 48533 |
| 2025-08-26 | BNTX | 104.83 | 0.83 | 0.08 | 48650 |
| 2025-08-27 | BNTX | 103.28 | 0.84 | 3.93 | 48516 |
| 2025-08-28 | BNTX | 101.94 | 0.87 | 0.72 | 49677 |
| 2025-08-29 | BNTX | 100.04 | 0.87 | 1.74 | 49668 |
| 2025-09-02 | BNTX | 100.65 | 0.87 | 0.88 | 49767 |
| 2025-09-03 | BNTX | 100.42 | 0.87 | 6.52 | 49895 |
| 2025-09-04 | BNTX | 104.06 | 0.88 | 0.33 | 50110 |
| 2025-09-05 | BNTX | 112.53 | 0.88 | 0.21 | 50141 |
| 2025-09-08 | BNTX | 102.44 | 0.85 | 0.69 | 51258 |
| 2025-09-09 | BNTX | 102.18 | 0.85 | 3.91 | 51804 |
| 2025-09-10 | BNTX | 101.06 | 0.87 | 0.58 | 52555 |
| 2025-09-11 | BNTX | 104.31 | 0.87 | 0.62 | 52760 |
| 2025-09-12 | BNTX | 96.73 | 0.86 | 2.06 | 54750 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | BNTX | 113.50 | -123.1 | -1130.4 | -4.18 |
| 2025-08-18 | BNTX | 112.55 | -126.8 | -1060.3 | -4.18 |
| 2025-08-19 | BNTX | 111.40 | -126.8 | -1064.7 | -4.19 |
| 2025-08-20 | BNTX | 111.27 | -126.8 | -1092.3 | -4.19 |
| 2025-08-21 | BNTX | 110.69 | -126.8 | -1071.0 | -4.12 |
| 2025-08-22 | BNTX | 110.95 | -126.8 | -1099.5 | -4.12 |
| 2025-08-25 | BNTX | 105.16 | -126.8 | -888.9 | -4.12 |
| 2025-08-26 | BNTX | 104.79 | -96.7 | -1047.5 | -4.10 |
| 2025-08-27 | BNTX | 103.00 | -96.7 | -967.6 | -4.10 |
| 2025-08-28 | BNTX | 101.93 | -96.7 | -994.0 | -4.10 |
| 2025-08-29 | BNTX | 100.18 | -96.7 | -967.1 | -4.10 |
| 2025-09-02 | BNTX | 100.65 | -96.7 | -1075.2 | -4.08 |
| 2025-09-03 | BNTX | 100.39 | -96.7 | -984.4 | -4.08 |
| 2025-09-04 | BNTX | 103.59 | -96.7 | -1127.3 | -4.08 |
| 2025-09-05 | BNTX | 112.46 | -96.7 | -1326.5 | -4.08 |
| 2025-09-08 | BNTX | 102.66 | -96.7 | -679.1 | -4.08 |
| 2025-09-09 | BNTX | 102.14 | -96.7 | -927.6 | -4.11 |
| 2025-09-10 | BNTX | 101.04 | -96.7 | -891.6 | -4.11 |
| 2025-09-11 | BNTX | 104.31 | -96.7 | -1050.2 | -4.11 |
| 2025-09-12 | BNTX | 96.73 | -96.7 | -624.8 | -4.11 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | BNTX | 0.00 | 2.10 | 2.56 |
| 2025-08-18 | BNTX | 0.00 | 2.17 | 2.55 |
| 2025-08-19 | BNTX | 0.00 | 2.17 | 2.55 |
| 2025-08-20 | BNTX | 0.00 | 2.17 | 2.55 |
| 2025-08-21 | BNTX | 0.00 | 2.17 | 2.55 |
| 2025-08-22 | BNTX | 0.00 | 2.17 | 2.55 |
| 2025-08-25 | BNTX | 0.00 | 3.59 | 2.55 |
| 2025-08-26 | BNTX | 0.00 | 3.59 | 2.55 |
| 2025-08-27 | BNTX | 0.00 | 3.59 | 2.67 |
| 2025-08-28 | BNTX | 0.00 | 3.59 | 2.67 |
| 2025-08-29 | BNTX | 0.00 | 3.59 | 2.67 |
| 2025-09-02 | BNTX | 0.00 | 3.55 | 2.67 |
| 2025-09-03 | BNTX | 0.00 | 3.55 | 2.67 |
| 2025-09-04 | BNTX | 0.00 | 3.55 | 2.67 |
| 2025-09-05 | BNTX | 0.00 | 3.55 | 2.67 |
| 2025-09-08 | BNTX | 0.00 | 3.41 | 2.67 |
| 2025-09-09 | BNTX | 0.00 | 3.41 | 2.67 |
| 2025-09-10 | BNTX | 0.00 | 3.41 | 2.67 |
| 2025-09-11 | BNTX | 0.00 | 3.41 | 2.54 |
| 2025-09-12 | BNTX | 0.00 | 3.41 | 2.54 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.82
Avg. EPS Est. Current Quarter
0.03
Avg. EPS Est. Next Quarter
-0.97
Insider Transactions
Institutional Transactions
3.41
Beta
1.47
Average Sales Estimate Current Quarter
1015
Average Sales Estimate Next Quarter
944
Fair Value
Quality Score
57
Growth Score
36
Sentiment Score
5
Actual DrawDown %
79.2
Max Drawdown 5-Year %
-82.2
Target Price
141.23
P/E
Forward P/E
PEG
P/S
7.44
P/B
1.07
P/Free Cash Flow
EPS
-1.6
Average EPS Est. Cur. Y
-4.11
EPS Next Y. (Est.)
-3.75
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-12.21
Relative Volume
6.7
Return on Equity vs Sector %
-26.7
Return on Equity vs Industry %
-13.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.07
EBIT Estimation
-624.8
BioNTech SESector: Healthcare
Industry: Biotechnology
Employees: 6772
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
stock quote shares BNTX – BioNTech SE Stock Price stock today
news today BNTX – BioNTech SE stock forecast ,stock prediction 2023 2024 2025
marketwatch BNTX – BioNTech SE yahoo finance google finance
stock history BNTX – BioNTech SE invest stock market
stock prices BNTX premarket after hours
ticker BNTX fair value insiders trading